Savolitinib was developed as a monotherapy for NSCLC with MET alterations, and in combination with epidermal growth factor receptor (EGFR) inhibitors for patients who developed resistance to EGFR–TKIs because of MET alterations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.